StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Fate Therapeutics

Fate Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Fate Therapeutics figures

See a number that looks wrong?